Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

A Comprehensive Protocol Resource for Performing Pooled shRNA and CRISPR Screens.

Cluse LA, Nikolic I, Knight D, Madhamshettiwar PB, Luu J, Cowley KJ, Semple T, Arnau GM, Shortt J, Johnstone RW, Simpson KJ.

Methods Mol Biol. 2018;1725:201-227. doi: 10.1007/978-1-4939-7568-6_17.

PMID:
29322420
2.

BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1.

Hogg SJ, Vervoort SJ, Deswal S, Ott CJ, Li J, Cluse LA, Beavis PA, Darcy PK, Martin BP, Spencer A, Traunbauer AK, Sadovnik I, Bauer K, Valent P, Bradner JE, Zuber J, Shortt J, Johnstone RW.

Cell Rep. 2017 Feb 28;18(9):2162-2174. doi: 10.1016/j.celrep.2017.02.011.

3.

BET Inhibition Induces Apoptosis in Aggressive B-Cell Lymphoma via Epigenetic Regulation of BCL-2 Family Members.

Hogg SJ, Newbold A, Vervoort SJ, Cluse LA, Martin BP, Gregory GP, Lefebure M, Vidacs E, Tothill RW, Bradner JE, Shortt J, Johnstone RW.

Mol Cancer Ther. 2016 Sep;15(9):2030-41. doi: 10.1158/1535-7163.MCT-15-0924. Epub 2016 Jul 12.

4.

Functional-genetic dissection of HDAC dependencies in mouse lymphoid and myeloid malignancies.

Matthews GM, Mehdipour P, Cluse LA, Falkenberg KJ, Wang E, Roth M, Santoro F, Vidacs E, Stanley K, House CM, Rusche JR, Vakoc CR, Zuber J, Minucci S, Johnstone RW.

Blood. 2015 Nov 19;126(21):2392-403. doi: 10.1182/blood-2015-03-632984. Epub 2015 Oct 7.

5.

An intact immune system is required for the anticancer activities of histone deacetylase inhibitors.

West AC, Mattarollo SR, Shortt J, Cluse LA, Christiansen AJ, Smyth MJ, Johnstone RW.

Cancer Res. 2013 Dec 15;73(24):7265-76. doi: 10.1158/0008-5472.CAN-13-0890. Epub 2013 Oct 24.

6.

Molecular and biologic analysis of histone deacetylase inhibitors with diverse specificities.

Newbold A, Matthews GM, Bots M, Cluse LA, Clarke CJ, Banks KM, Cullinane C, Bolden JE, Christiansen AJ, Dickins RA, Miccolo C, Chiocca S, Kral AM, Ozerova ND, Miller TA, Methot JL, Richon VM, Secrist JP, Minucci S, Johnstone RW.

Mol Cancer Ther. 2013 Dec;12(12):2709-21. doi: 10.1158/1535-7163.MCT-13-0626. Epub 2013 Oct 3.

7.

Deciphering the molecular events necessary for synergistic tumor cell apoptosis mediated by the histone deacetylase inhibitor vorinostat and the BH3 mimetic ABT-737.

Wiegmans AP, Alsop AE, Bots M, Cluse LA, Williams SP, Banks KM, Ralli R, Scott CL, Frenzel A, Villunger A, Johnstone RW.

Cancer Res. 2011 May 15;71(10):3603-15. doi: 10.1158/0008-5472.CAN-10-3289. Epub 2011 Mar 11.

8.

Asymmetric cell division of T cells upon antigen presentation uses multiple conserved mechanisms.

Oliaro J, Van Ham V, Sacirbegovic F, Pasam A, Bomzon Z, Pham K, Ludford-Menting MJ, Waterhouse NJ, Bots M, Hawkins ED, Watt SV, Cluse LA, Clarke CJ, Izon DJ, Chang JT, Thompson N, Gu M, Johnstone RW, Smyth MJ, Humbert PO, Reiner SL, Russell SM.

J Immunol. 2010 Jul 1;185(1):367-75. doi: 10.4049/jimmunol.0903627. Epub 2010 Jun 7.

9.

The histone deacetylase inhibitors LAQ824 and LBH589 do not require death receptor signaling or a functional apoptosome to mediate tumor cell death or therapeutic efficacy.

Ellis L, Bots M, Lindemann RK, Bolden JE, Newbold A, Cluse LA, Scott CL, Strasser A, Atadja P, Lowe SW, Johnstone RW.

Blood. 2009 Jul 9;114(2):380-93. doi: 10.1182/blood-2008-10-182758. Epub 2009 Apr 21.

10.

Defining the target specificity of ABT-737 and synergistic antitumor activities in combination with histone deacetylase inhibitors.

Whitecross KF, Alsop AE, Cluse LA, Wiegmans A, Banks KM, Coomans C, Peart MJ, Newbold A, Lindemann RK, Johnstone RW.

Blood. 2009 Feb 26;113(9):1982-91. doi: 10.1182/blood-2008-05-156851. Epub 2008 Dec 5.

11.

Characterisation of the novel apoptotic and therapeutic activities of the histone deacetylase inhibitor romidepsin.

Newbold A, Lindemann RK, Cluse LA, Whitecross KF, Dear AE, Johnstone RW.

Mol Cancer Ther. 2008 May;7(5):1066-79. doi: 10.1158/1535-7163.MCT-07-2256. Erratum in: Mol Cancer Ther. 2014 Jun;13(6):1675.

12.

Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma.

Lindemann RK, Newbold A, Whitecross KF, Cluse LA, Frew AJ, Ellis L, Williams S, Wiegmans AP, Dear AE, Scott CL, Pellegrini M, Wei A, Richon VM, Marks PA, Lowe SW, Smyth MJ, Johnstone RW.

Proc Natl Acad Sci U S A. 2007 May 8;104(19):8071-6. Epub 2007 Apr 30.

13.

SOCS3 is a critical physiological negative regulator of G-CSF signaling and emergency granulopoiesis.

Croker BA, Metcalf D, Robb L, Wei W, Mifsud S, DiRago L, Cluse LA, Sutherland KD, Hartley L, Williams E, Zhang JG, Hilton DJ, Nicola NA, Alexander WS, Roberts AW.

Immunity. 2004 Feb;20(2):153-65.

14.

Rac2-deficient mice display perturbed T-cell distribution and chemotaxis, but only minor abnormalities in T(H)1 responses.

Croker BA, Handman E, Hayball JD, Baldwin TM, Voigt V, Cluse LA, Yang FC, Williams DA, Roberts AW.

Immunol Cell Biol. 2002 Jun;80(3):231-40.

PMID:
12067410
15.

The Rac2 guanosine triphosphatase regulates B lymphocyte antigen receptor responses and chemotaxis and is required for establishment of B-1a and marginal zone B lymphocytes.

Croker BA, Tarlinton DM, Cluse LA, Tuxen AJ, Light A, Yang FC, Williams DA, Roberts AW.

J Immunol. 2002 Apr 1;168(7):3376-86.

Supplemental Content

Loading ...
Support Center